MedPath

Resonance Health Ltd

Ownership
-
Employees
18
Market Cap
-
Website
Introduction

Resonance Health Ltd is a healthcare company specializing in the development and commercialization of technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment. Its product includes FerriScan, a non-invasive liver diagnostic technology used for the measurement of iron in the liver, Cardiac T2, and HepaFat-Scan. It also has several AI-assisted SaMDs including FerriSmart, HepaFat-AI, and LiverSmart. The company's business segments are; Services which derives key revenue, Research and development, Corporate, Clinical Research Organization (CRO), and TrialsWest. Geographically, it generates maximum revenue from the Asia Pacific and the rest from North America, and Europe, Middle East and Africa (EMEA) regions.

Clinical Trials

1

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

No trials found

News

Resonance Health Secures $13.775 Million Clinical Trial Contract with Sun Pharma

Resonance Health has been contracted by Sun Pharmaceutical Industries for a clinical trial in Australia, valued at AUD $13.775 million.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.